ISRCTN78808170已完成未知
Can the use of the Peroxisome Proliferator-Activated Receptor (PPAR)-gamma agonist rosiglitazone reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndrome? A randomised controlled trial
Academic Medical Centre (AMC) (The Netherlands)0 个研究点目标入组 15 人开始时间: 2007年2月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •2. Aged more than 18 years
- •3. Documented HIV-1 infection
- •4. HIV-Ribonucleic Acid (RNA) less than 50 copies/ml
- •5. Clinical evidence of lipodystrophy
- •6. More than 36 weeks no use of a protease inhibitor
- •7. More than 24 weeks no use of d4T
- •8. More than 12 weeks on a stabile regimen
排除标准
- •1. Active hepatitis
- •2. Alanine aminotransferase (ALAT)/Aspartate aminotransferase (ASAT) more than 2.5 x above normal level
- •3. Total bilirubin 2.5 x above normal level
- •4. Lactate 2.5 x above normal level
- •5. Anaemia
- •6. Use of medication influencing metabolism/blood clotting
研究者
相似试验
进行中（未招募）
1 期
The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer - PPAREUCTR2006-001398-44-GBBarts and The London NHS Trust49
进行中（未招募）
不适用
The effect of peroxisome proliferator activator receptor ? agonist pre-treatment on pegylated interferon-a2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - - HEPAR studyChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2007-007075-16-NLVU university medical center50
撤回
不适用
The effect of peroxisome proliferator activator receptor * agonist pre-treatment on pegylated interferon-*2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trialViral liver disease1001965410047438Hepatitis CNL-OMON31787Vrije Universiteit Medisch Centrum50
进行中（未招募）
不适用
Effects of the activation of PPARs in the orphan hepatic disease primary biliary cirrhosisp to 67% of PBC patients have an incomplete biochemical response to UDCA and remain at increased risk for progression to cirrhosis and liver-related death. In this study we will prospectively examine the therapeutic effects of bezafibrate (a pan-agonist activating PPARalpha/delta/gamma) in patients with early-stage PBC with a specific focus on improvement of liver functions, inflammation, lipid profile, oxidative status and endothelial function.EUCTR2011-004681-15-ATMedizinische Universität Graz
招募中
3 期
A clinical trial to study the effect of antidiabetic drug Pioglitazone in patients with Type 2 Diabetes Mellitus when given as low dose or twice weekly doseCTRI/2024/02/062959Dr Deepak Anand R